ABSTRACT
INTRODUCTION
Patients with diabetes exhibit higher rate of depression compared to other peoples (1) . Comorbid diabetes and depression are associated with hyperglycemia and poor glycemic control (2) , with an accelerated progression of complication associated with diabetes (3) , and increased risk of mortality (4) . Selective serotonin reuptake inhibitors(SSRIs) are the drugs of choice for the treatment of depression, and the majority of clinical studies support their use in diabetes and depression (5) . Diabetic patients treated by SSRIs can exhibit reduced fasting glucose levels, reduced body weight and improved glycemic control compared with diabetic patients using other antidepressants. Also, selective serotonin reuptake inhibitors thereby effectively reduces depression and prevents its recurrence in diabetic patients (5) . Similar to other antidepressant, SSRLs can impact blood glucose level particularly in diabetic patients, with an increase in the frequency and severity of hypoglycemia with absence of hypoglycemic symptoms (7) . Hypoglycemia associated with SSRIs thereby may be particularly a problem for intensively managed type 1 and type 2 diabetic patients. Intensive insulin or glucose lowering therapies aimed at maintaining tight glycemic control are associated with a three-to four fold increase in the incidence of sever hypoglycemia with SSRIs treatment (8) . As a result of recurrent hypoglycemia, the hormonal counterreglulatory responses normally elicited by decrease of plasma glucose become impaired, thus increasing the risk for future bouts of hypoglycemia (9) . Impaired hypoglycemic counterregulation is a component of the clinical syndrome of hypoglycemia-associated with autonomic failure (9) . Serotonergic mechanisms have long been known to modulate neuroendocrinal responses, which are critical to hypoglycemia counterregulation. The association between SSRIs and hypoglycemia may be due to SSRIs-induced impairment of counterregulation mechanisms. Treatment with SSRIs in humans suppresses basal sympathetic nervous system activity (10) . Also serotonin neurons located in the caudal hindbrain are directly sensitive to changes in glucose availability (11).
Therefore, SSRIs may reduce the sensitivity of glucose sensing neurons that contributes to the activation of hormonal counterreglulatory responses.
(11)
The aim of the present work was to study the effect of SSRIs sertraline, on blood glucose regulation, autonomic and neuroendocrinal responses in adult normal and diabetic male albino rats.
MATERIALS & METHODS
36 adult male albino rats weighing from 230-275gm were housed individually at room temperature with maintained dark light schedule (12am: 12pm hours). Rats were fed milk and bread and has free water access: The rats were divided into two groups. A-Normal group: contained 18 rats subdivided into three equal subgroups each containing 6 rats: Group (1): The normal control rats were administrated 1/2 ml oral saline through small intragastric tube. Group (2): Rats were treated by oral sertraline(Apex Pharma) through small intragstric tube in a dose of 30mg/kg/day (12) for one week. Groups (3): Rats were treated by oral sertraline through small intragastric tube in a dose of 30mg/day for three weeks. B-Diabetic group contained 18 rats.
Diabetes was induced by single intraperitoneal injection of streptozotocin 50mg/kg (13). The rats were subdivided into three equal groups each containing 6 rats.
Group (1):
The control diabetic group, rats were administrated 1/2 ml oral saline through small intragastric tube. 
Statistical analysis
Results were tabulated as mean values + DS, and analysis was performed. Comparison between studied groups were performed with independent samples student t-test. Analysis of variance was calculated, P values of <0.05 were considered statistically significant.
RESULTS
The results of the present work are shown in table (1): Serum glucose level:
Sertraline treatment for one week showed, significant reduction of blood glucose level in normal and diabetic rats compared with the control, P< 0.05. Also, there was significant reduction of blood glucose level in normal and diabetic groups treated by sertraline for three weeks compared with the control, (P<0.05), Fig (1) .
Epinephrine level:
The results showed significant increase in levels of epinephrine both normal and diabetic rats, after one or three weeks sertraline treatment compared with control, P<0.05, (Fig  (2) Norepinephrine level:
The results showed non significant change in norepinephrine level after one week of sertraline treatment in normal and diabetic rats. There was significant increase of norepinephrine level after three weeks of sertraline treatment in normal and diabetic groups compared with the control, p<0.05, Fig (3) 
Glucagon level:
The results showed non significant change in glucagon level after one week of sertraline treatment in normal and diabetic groups. Normal and diabetic groups treated by sertraline for three weeks showed significant increase in glucagon level compared with the control, p< 0.05, Fig (4) .
ACTH, corticosterone and insulin levels:
The results showed non significant change in their levels either after one or three weeks of treatment by sertraline, in normal and diabetic groups, Fig (5,6,7 ).
Body weight:
The results showed non significant change in body weight both in normal and diabetic rats after one week and three weeks of sertraline treatment in normal and diabetic groups compared with the control, Fig  (8) . 
DISCUSSION
The use of selective serotonin reuptake inhibitors sertraline treatment in the diabetic patients is accompanied by intensive glucose lowering might exacerbate the risk of sever hypoglycemia (5) . The results of the present study showed that, continuous treatment with SSRI sertraline for three weeks, stimulated the release of epinephrine, norepinephrine and glucagon hormones. One week treatment by sertraline stimulated adrenomedullary response specifically, as there was no effect of sertraline on norepinephrine, glucagon, ACTH, corticosterone, insulin or body weight in normal and diabetic rats. The reduction of blood glucose without change in insulin level by SSRI sertraline, may be due to the effect of sertraline increased insulin sensitivity. It was reported that SSRIs caused rapid and significant elevation in hepatic glucose uptake and increased hepatic glycogen levels in presence of hyperinsulinemia, but not in normal insulin level . The enhancement of glucagon secretion after three weeks sertraline treatment may be secondary to the overall enhanced sympatho-adrenomedullary responses in three weeks treated rats (36) . It was observed that, there was no effect of sertraline treatment on ACTH or corticosterone. It is possible that sertraline-induced hypothalamicpituitary-adrenal axis activation and C-ƒos expression become blunted by daily treatment. Also, the selective effect of sertraline on adrenomedullary activation without any alteration in ACTH or corticosterone, may be due to the specific action of sertraline on the adrenal medulla (37) . The results showed no effect of sertraline on body weight after one or three weeks treatment. It is possible that the anorectic action of sertraline had no effect on powerful feeding response due to glucose deficit. Also, chronic blockade of serotonin reuptake transporter does appear to modulate the neuronal circuitry required for the feeding response elicited by hypoglycemia (37) . This may be due to population of rostrally projecting hindbrain catecholamine neurons, whose activity and function may not be affected by sertraline (38) .
Conclusion and recommendation:
It 
